Genetic signatures always suggest undertreatment? Experience with PAM50

Sales, C. ; Vieira, I. ; Cassiano, M. ; Oliveira, C. ; Vieira, C. ; Ferreira, M. ; Rodrigues, A. ; Ferreira, A. ; Pousa, M.I. ; Couto, R. ; Leal, C. ; Abreu, J. ; Teixeira, M. ; Pereira, D. ; Sousa, S. ; Abreu, M.H.

England: Elsevier Ltd

Texto completo disponível

215PGenetic signatures always suggest undertreatment? Experience with PAM50

Sales, C ; Vieira, I ; Cassiano, M ; Oliveira, C ; Vieira, C ; Ferreira, M ; Rodrigues, A ; Ferreira, A ; Pousa, M I ; Couto, R ; Leal, C ; Abreu, J ; Teixeira, M ; Pereira, D ; Sousa, S ; Abreu, M H

Oxford University Press

Texto completo disponível

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Kim, E.S. ; Velcheti, V. ; Mekhail, T. ; Leal, T.A. ; Dowell, J.E. ; Tsai, M.L. ; Dakhil, C.S.R. ; Stella, P. ; Shen, V. ; Hu, S. ; Paul, S.M. ; Shames, D.S. ; Schleifman, E. ; Fabrizio, D.A. ; Yun, C. ; Phan, S. ; Socinski, M.A.

England: Elsevier Ltd

Texto completo disponível

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy

Leal, T.A. ; Spira, A.I. ; Blakely, C. ; He, K. ; Berz, D. ; Richards, D. ; Uyeki, J. ; Savage, A. ; Roque, T. ; Massarelli, E. ; Jotte, R.M. ; Chen, I. ; Christensen, J. ; Olson, P. ; Tassell, V. ; Horn, L.

England: Elsevier Ltd

Texto completo disponível

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Wakelee, H. ; Reckamp, K.L. ; Leal, T.A. ; Patel, S.P. ; Blumenschein, G. ; Shum, E. ; Nieva, J. ; Oxnard, G. ; Sanborn, R.E. ; Waqar, S. ; Zeman, K. ; Dukart, G. ; Harrow, K. ; Liang, C. ; Holzhausen, A. ; Horn, L.

England: Elsevier Ltd

Texto completo disponível

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H. ; de Marinis, F. ; Dumoulin, D. ; Reynolds, C. ; Theelen, W.S.M.E. ; Percent, I. ; Gutierrez Calderon, V. ; Johnson, M.L. ; Madroszyk-Flandin, A. ; Garon, E.B. ; He, K. ; Planchard, D. ; Reck, M. ; Popat, S. ; Herbst, R.S. ; Leal, T.A. ; Shazer, R.L. ; Yan, X. ; Harrigan, R. ; Peters, S.

England: Elsevier Ltd

Sem texto completo

P-157 Assessing fitness for systemic therapy in hepatocellular carcinoma: Evaluating time on treatment according to Child-Pugh classification, model for end-stage liver disease score, and AFP level

Staum, B. ; Hu, J. ; Leal, A. ; Kim, S. ; Purcell, W. ; Lieu, C. ; Messersmith, W. ; Davis, S.

Texto completo disponível

Outcomes of pancreatic adenocarcinoma resection between initial resectable and borderline/unresectable patients undergoing neoadjuvant chemotherapy: a two-center study

Moreira-Pinto, J. ; Godinho, J. ; Simões, P. ; da Costa, L. Leal ; Mata, I. ; Branco, F. ; Pulido, C. ; Costa Santos, M. ; Cunha, C. ; Padrão, T. ; Lopes, F. ; Teixeira, J. ; Rodrigues, T. ; Casa-Nova, M. ; Maio, R. ; Passos-Coelho, J.

England: Elsevier Ltd

Texto completo disponível

1133P Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC

Zhang, J. ; Leventakos, K. ; Leal, T.A. ; Pennell, N. ; Barve, M. ; Paulson, A.S. ; Bazhenova, L. ; Johnson, M.L. ; Chao, R.C. ; Velastegui, K. ; Qian, C. ; Bleker, W. ; Spira, A.

Texto completo disponível

1820P Taxane-related skin toxicity: Analysis of an in vivo and 3D in vitro model study of the impact of paclitaxel on skin

Perez-Leal, M. ; Perez Fidalgo, J.A. ; Sanz, C. ; Poveda, J. ; Milara, J. ; Martinez, P. ; Cervantes, A. ; Cortijo, J.

Elsevier Ltd

Texto completo disponível